Возможности таргетной терапии при лечении нейроэндокринных опухолей желудочно-кишечного тракта и поджелудочной железы

1. Oberg K, Astrup L, Eriksson B et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumors (including bronchopulmonary and thymic neoplasms). Part I: general overview. Acta Oncol 2004; 43 (7): 617–25.
2. Terris B, Scoazec JY, Rubbia L et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998; 32 (2): 133–8.
3. Papouchado B, Erickson L, Rohlinger A. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 2005; 18 (10): 1329–35.
4. Wang L, Iquat A, Axiotis C. Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl Immunohistochem Mol Morphol 2002; 10 (2): 139–46.
5. Manley P, Martiny-Baron G, Schlaeppi J. Therapies directed at vascular endothelial growth factor. Expert Opin Investig Drugs 2002; 11 (12): 1715–36.
6. Yao JC, Phan A, Hoff PM et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26 (8): 1316–23.
7. Kunz P, Kuo T, Kaiser H. A Phase II study of capecitabine, oxaliplatin and bevacizumab for metastatic or unresectable neuroendocrine tumors: preliminary results. Proc ASCO 2008; 26: 15502.
8. Venook A, Ko A, Tempero M et al. Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. Proc ASCO 2008; 26: 15545.
9. Kulke M, Stuart K, Earle C et al. A phase II study of temozolamide and bevacizumab in patients with advanced neuroendocrine tumors. Proc ASCO 2006; 24: 4044.
10. Capdevila J, Salazar R. Molecular target therapy methods in treatment of gastrointestinal neuroendocrine tumors. Targ Oncol 2009; 4: 287–96.
11. Kulke M, Leuz H, Meropol N et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: 3403–10.
12. Raymond E, Raoul J, Niccoli P. Phase III randomized double-blind trial of sunitinib vs placebo in patients with progressive, well-differentiated malignant pancreatic islet cell tumors. World Congress on Gastrointestinal Cancers 2009. 0013.
13. Strosberg J, Campos T, Kvols L. Phase II study of sunitinib malate following hepatic artery embolization for metastatic gastroenteropancreatic neuroendocrine tumors. Proc ASCO 2009.
14. Hobday T, Rubin J, Hoten K et al. MC044h, a phase II trial of sorafenib in patients with metastatic neuroendocrine tumors: A phase II Consortium (P2C) study. Proc ASCO 2007; 25 (185): 4505.
15. Kulke M, Stuart K, Enzingen P et al. Phase II study of temozolamide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006; 24 (3): 401–6.
16. Hobday T, Holen K, Donehower R et al. A phase II trial of gefitinib in patients with progressive metastatic neuroendocrine tumors: A phase II Consortium (P2C) study. Proc ASCO 2006; 24 (185): 4043.
17. Aoki M, Blazek E, Vogt P. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Poc Natl Acad Sci USA 2001; 98: 136–41.
18. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by angiogenesis: involvment of vascular endothelial growth factor. Nat Med 2002; 8 (2): 128–35.
19. Красильников М.А., Жуков Н.Ф. Сигнальный путь mTOR: новая мишень терапии опухолей. Совр. онкол. 2010; 12 (2): 9–16.
20. Duran I, Kortmansky J, Singh D et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2007; 95 (9): 1148–54.
21. Yao J, Phan A, Chang D et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low to intermediate grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26 (26): 4311–18.
22. Tabemero J, Rojo F, Calvo E et al. Dose- and shedule-dependent inhibition oft he mammalian target rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008; 26 (10): 1603–10.
23. Yao J, Lombard-Bohas C, Baudin E et al. A phase II trial of daily oral RAD001 (everolimus) in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy. ASCO GI 2009: 1603–10.
24. Raz I, Rubinger D, Popovtzer M et al. Octreotide prevents the early increase in renal insulin-like growth factor binding protein 1 in streptozotocin diabetic rats. Diabetes 1998; 47 (6): 924–30.

Н.Ф.Орел, А.А.Маркович

ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва